Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 7/20 | 0.66 |
| ▸ | CHRND | Q07001 | 5/20 | 0.59 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.59 |
| ▸ | CHRNG | P07510 | 1/20 | 0.59 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1875301 | 0.94 | GRIA1 (0.59) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL1875305 | 0.94 | GRIA1 (0.59) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL14102592 | 0.91 | EPHX2 (0.59) | GRIA1CHRND | |
| SCHEMBL14102642 | 0.91 | EPHX2 (0.59) | GRIA1CHRND | |
| SCHEMBL14102844 | 0.91 | EPHX2 (0.59) | GRIA1CHRND | |
| SCHEMBL9519035 | 0.88 | CHRNB2 (0.69) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL6438848 | 0.88 | CHRNB2 (0.69) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL4740492 | 0.86 | CHRND (0.55) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL4785903 | 0.86 | CHRND (0.55) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| Hydrochloric Acid SCHEMBL1879093 | 0.86 | GRIA1 (0.66) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3434259-A1 | AMINO ACID LIPIDS AND USES THEREOF | Marina Biotech, Inc. (US) | 2019-01-30 | — | — | EP | disclosed |
| US-9731016-B2 | Tyrosine-based lipids for delivery of therapeutics | MARINA BIOTECH, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9731016-B2 | Tyrosine-based lipids for delivery of therapeutics | MARINA BIOTECH, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160206739-A1 | TYROSINE-BASED LIPIDS FOR DELIVERY OF THERAPEUTICS | MARINA BIOTECH INC (US) | 2016-07-21 | — | — | US | disclosed |
| US-20160206739-A1 | TYROSINE-BASED LIPIDS FOR DELIVERY OF THERAPEUTICS | MARINA BIOTECH INC (US) | 2016-07-21 | — | — | US | disclosed |
| US-9339461-B2 | Arginine-based lipids for delivery of therapeutics | MARINA BIOTECH, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9339461-B2 | Arginine-based lipids for delivery of therapeutics | MARINA BIOTECH, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150209283-A1 | PROCESSES AND COMPOSITIONS FOR LIPOSOMAL AND EFFICIENT DELIVERY OF GENE SILENCING THERAPEUTICS | MARINA BIOTECH INC (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150209283-A1 | PROCESSES AND COMPOSITIONS FOR LIPOSOMAL AND EFFICIENT DELIVERY OF GENE SILENCING THERAPEUTICS | MARINA BIOTECH INC (US) | 2015-07-30 | — | — | US | disclosed |
| EP-2349210-B1 | PROCESSES AND COMPOSITIONS FOR LIPOSOMAL AND EFFICIENT DELIVERY OF GENE SILENCING THERAPEUTICS | MARINA BIOTECH INC (US) | 2015-03-18 | — | — | EP | disclosed |
| US-20110177160-A1 | Amino acid lipids and uses thereof | MARINA BIOTECH, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-7939505-B2 | Amino acid lipids and uses thereof | MARINA BIOTECH, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939505-B2 | Amino acid lipids and uses thereof | MARINA BIOTECH, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| WO-2010059829-A2 | COMPOSITIONS AND METHODS FOR TRIGGERED RELEASE RNA THERAPEUTICS | MDRNA, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
| US-20100112042-A1 | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics | MDRNA, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100112042-A1 | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics | MDRNA, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| WO-2010045512-A2 | PROCESSES AND COMPOSITIONS FOR LIPOSOMAL AND EFFICIENT DELIVERY OF GENE SILENCING THERAPEUTICS | MDRNA , INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| US-20080317839-A1 | AMINO ACID LIPIDS AND USES THEREOF | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080317839-A1 | AMINO ACID LIPIDS AND USES THEREOF | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2008-12-25 | — | — | US | disclosed |
| WO-2008137758-A2 | AMINO ACID LIPIDS AND USES THEREOF | MDRNA, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160206739-A1 | TYROSINE-BASED LIPIDS FOR DELIVERY OF THERAPEUTICS | ABL1, LCK, ERBB2 | GRIA1 1430/4885CHRND 4783/4885CHRNA1 4738/4885 |
| US-20080317839-A1 | AMINO ACID LIPIDS AND USES THEREOF | AADAT, AARS1, ABAT | GRIA1 1288/4885CHRND 4881/4885CHRNA1 4854/4885 |
| US-20150209283-A1 | PROCESSES AND COMPOSITIONS FOR LIPOSOMAL AND EFFICIENT DELIVERY OF GENE SILENCING THERAPEUTICS | SLC27A2, LYPLA2, SLC27A1 | GRIA1 1607/4885CHRND 4681/4885CHRNA1 4159/4885 |
| US-20100112042-A1 | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics | SLC27A2, LYPLA2, SLC47A2 | GRIA1 1827/4885CHRND 4649/4885CHRNA1 4378/4885 |
| US-20110177160-A1 | Amino acid lipids and uses thereof | AADAT, AARS1, ABAT | GRIA1 1288/4885CHRND 4881/4885CHRNA1 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.